Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Nichols

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The FEBS Journal|March 13, 2021
The lysosomal endopeptidases Cathepsin D and L are selective and effective proteases for the middle-down characterization of antibodiesTomislav Čaval, Elizabeth Sara Hecht, Wilfred Tang, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 21, 2015
Optical coherence tomography predicts visual outcome for pituitary tumorsHelen V Danesh-Meyer, Aaron Wong, Taras Papchenko, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 29, 2023
STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary AngioedemaVahe Bedian, Nikolaos Biris, Charles Omer, et al.
The Journal of Clinical Investigation|December 18, 2003
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistanceHaiyan Xu, Glenn T Barnes, Qing Yang, et al.
Journal of Neuromuscular Diseases|November 20, 2018
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular DystrophyErika Finanger, Krista Vandenborne, Richard S Finkel, et al.
The Journal of Biological Chemistry|January 30, 2002
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidaseChad Vickers, Paul Hales, Virendar Kaushik, et al.
Elife|September 28, 2021
PGFinder, a novel analysis pipeline for the consistent, reproducible, and high-resolution structural analysis of bacterial peptidoglycansAnkur V Patel, Robert D Turner, Aline Rifflet, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2011
Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodentsHiroshi Nagabukuro, Katherine L Villa, L Alexandra Wickham, et al.
Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry|February 22, 2024
The global distribution of special needs dentistry across dental school curriculaTamara Scepanovic, Sarah Mati, Anna L C Ming, et al.
Neuromuscular Disorders : NMD|March 8, 2021
Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trialRichard S Finkel, Erika Finanger, Krista Vandenborne, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The FEBS Journal|March 13, 2021
The lysosomal endopeptidases Cathepsin D and L are selective and effective proteases for the middle-down characterization of antibodiesTomislav Čaval, Elizabeth Sara Hecht, Wilfred Tang, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 21, 2015
Optical coherence tomography predicts visual outcome for pituitary tumorsHelen V Danesh-Meyer, Aaron Wong, Taras Papchenko, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 29, 2023
STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary AngioedemaVahe Bedian, Nikolaos Biris, Charles Omer, et al.
The Journal of Clinical Investigation|December 18, 2003
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistanceHaiyan Xu, Glenn T Barnes, Qing Yang, et al.
Journal of Neuromuscular Diseases|November 20, 2018
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular DystrophyErika Finanger, Krista Vandenborne, Richard S Finkel, et al.
The Journal of Biological Chemistry|January 30, 2002
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidaseChad Vickers, Paul Hales, Virendar Kaushik, et al.
Elife|September 28, 2021
PGFinder, a novel analysis pipeline for the consistent, reproducible, and high-resolution structural analysis of bacterial peptidoglycansAnkur V Patel, Robert D Turner, Aline Rifflet, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2011
Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodentsHiroshi Nagabukuro, Katherine L Villa, L Alexandra Wickham, et al.
Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry|February 22, 2024
The global distribution of special needs dentistry across dental school curriculaTamara Scepanovic, Sarah Mati, Anna L C Ming, et al.
Neuromuscular Disorders : NMD|March 8, 2021
Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trialRichard S Finkel, Erika Finanger, Krista Vandenborne, et al.
Pageof 4